Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this live activity for a maximum of 26.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 26.0 Contact Hours.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
This activity provides Category I CME and self-assessment credits toward Part 2 of the ABS MOC Program. For more information, please visit http://www.absurgery.org
The 36th Annual Miami Breast Cancer Conference®(MBC) is supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Genomic Health, Inc., Eisai, Lilly,Merck Sharp & Dohme Corp, Novartis Pharmaceuticals Corporation, Pacira Pharmaceuticals, Inc., Pfizer, Puma Biotechnology, Inc., and Seattle Genetics, Inc.
For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
36th Annual Miami Breast Cancer Conference®— Call for Poster Abstracts!
The Miami Breast Cancer Conference® (MBCC) program chair and co-chairs invite you to submit your abstracts for the 36th Annual Miami Breast Cancer Conference®, to be held March 7 to 10, 2019, at the Fontainebleau Miami Beach in Miami Beach, Florida.
The Abstract portal is now closed.
All poster abstract submissions must be made electronically through the MBCC’s online abstract submission system.
Abstracts should be a short description of your work and contain all the elements necessary to define your goals and results to the reader. All authors will be required to disclose all financial relationships through the online system, helping to ensure quality and unbiased presentations.
Share your research or best practices with your peers. Categories of submission include:
The program chair, co-chairs, and curriculum committee will evaluate the scientific quality of the submitted abstracts based on the following criteria: novelty of the research, significance of the findings, quality of the research, and clarity. Incomplete abstracts will not be reviewed.
Notification of acceptance or regret will be delivered via email to the presenters of each poster abstract by early January. Please note that an author is required to be present during the poster session.
If accepted for presentation, abstracts and posters will be available for viewing online on the 2019 MBCC website during and after the conference. Formal poster viewing sessions will be held in the evenings during the MBCC conference on Thursday and Friday, March 7 and 8, 2019. The presentation at the MBCC should reflect the submitted abstract; abstract title, authorship, and content of the presentation must match the submitted abstract.
All presenters must register to attend the 36th Annual Miami Breast Cancer Conference®. Please visit www.gotoper.com to register.
Note to Members of Industry
Posters presented at MBCC will be included as part of the continuing medical education (CME)/continuing education (CE)–certified conference sessions. The primary purpose of Physicians’ Education Resource®, LLC (PER®), CME/CE activities is to advance the professional development of our learners in order to increase knowledge and improve the diagnosis and treatment of patients. To maintain the flow of the most current information to our learners and serve the public interest, the content of PER® may include information planned, presented, or authored by employees of industry. PER® is committed to the integrity of the science presented at its CME/CE activities and employs a rigorous peer review process to ensure that integrity. PER® maintains control of all content and plans all its activities in compliance with the Accreditation Council for Continuing Medical Education Standards for Commercial Support.
Please note that for lead presenters, poster content will be limited to basic science research (eg, preclinical research, drug discovery) or the processes/methodologies of research, themselves unrelated to a specific disease or compound/drug.
The content of your poster must not be related to clinical applications of the research/discovery or clinical recommendations concerning the business lines or products of your employer. The content of the information with which you are involved will promote quality in healthcare or advances in science and will not promote a specific product or pharmaceutical/biotech company. Content for this poster must be fair, balanced, and unbiased. In addition, your poster discussions must permit full discussion of the therapeutic benefits and risks of the discovery.
Complete the abstract template provided on the 2019 MBCC website.
Components of the Abstract Body—Limit: 2500 Characters (1 table allowed)
Please submit any questions pertaining to abstract submissions to email@example.com using the subject line “MBCC Abstract QUESTION.”
Author Consent and Waiver of Claims
Each abstract author agrees and certifies that he or she waives any and all claims against Physicians’ Education Resource®, LLC, the sponsor of the 36th Annual Miami Breast Cancer Conference®, and any reviewer arising out of or relating to the abstract submission and review process, including but not limited to peer review and the grading of abstracts.
Cancer Summaries and Commentaries™: Update from Atlanta – Advances in the Treatment of Multiple Myeloma
Feb 28, 2019
Feb 28, 2019
Feb 28, 2019
23rd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma
February 28, 2019 - March 3, 2019